TECX Key Statistics, Chart & Performance
The current stock price of TECX is 21.1 USD. In the past month the price increased by 27.62%. In the past year, price decreased by -59.24%.
TECX Latest News, Press Relases and Analysis
TECX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.89 | 398.93B | ||
| AMGN | AMGEN INC | 15.14 | 178.34B | ||
| GILD | GILEAD SCIENCES INC | 14.77 | 150.05B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.2 | 115.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.05 | 75.90B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 894.31 | 60.26B | ||
| INSM | INSMED INC | N/A | 43.71B | ||
| NTRA | NATERA INC | N/A | 33.71B | ||
| BIIB | BIOGEN INC | 10.93 | 26.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.34 | 20.84B | ||
| INCY | INCYTE CORP | 15.94 | 20.09B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B |
Related stock screener links
About TECX
Company Profile
Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). The company is headquartered in Watertown, Massachusetts and currently employs 51 full-time employees. The company went IPO on 2018-06-21. The firm is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead asset, TX000045 (TX45), is a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). TX002100 (TX2100) is its second development candidate for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT).
Company Info
TECTONIC THERAPEUTIC INC
490 Arsenal Way, Suite 210
Watertown MASSACHUSETTS US
Employees: 51
Phone: 13396663320
TECTONIC THERAPEUTIC INC / TECX FAQ
What does TECX do?
Tectonic Therapeutic, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of therapeutic proteins and antibodies that modulate the activity of G protein-coupled receptors (GPCR). The company is headquartered in Watertown, Massachusetts and currently employs 51 full-time employees. The company went IPO on 2018-06-21. The firm is focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs). Leveraging its technology platform called GEODe (GPCRs Engineered for Optimal Discovery), the Company is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. The Company’s lead asset, TX000045 (TX45), is a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in Phase Ia/Ib clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF). TX002100 (TX2100) is its second development candidate for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT).
What is the current price of TECX stock?
The current stock price of TECX is 21.1 USD. The price increased by 0.57% in the last trading session.
Does TECTONIC THERAPEUTIC INC pay dividends?
TECX does not pay a dividend.
What is the ChartMill technical and fundamental rating of TECX stock?
TECX has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does TECTONIC THERAPEUTIC INC belong to?
TECTONIC THERAPEUTIC INC (TECX) operates in the Health Care sector and the Biotechnology industry.
Can you provide the number of employees for TECTONIC THERAPEUTIC INC?
TECTONIC THERAPEUTIC INC (TECX) currently has 51 employees.
What is TECTONIC THERAPEUTIC INC worth?
TECTONIC THERAPEUTIC INC (TECX) has a market capitalization of 394.99M USD. This makes TECX a Small Cap stock.
TECX Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to TECX. When comparing the yearly performance of all stocks, TECX is a bad performer in the overall market: 82.99% of all stocks are doing better.
TECX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TECX. While TECX seems to be doing ok healthwise, there are quite some concerns on its profitability.
TECX Financial Highlights
Over the last trailing twelve months TECX reported a non-GAAP Earnings per Share(EPS) of -3.86. The EPS increased by 60.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.3% | ||
| ROE | -25.16% | ||
| Debt/Equity | 0 |
TECX Forecast & Estimates
15 analysts have analysed TECX and the average price target is 81.35 USD. This implies a price increase of 285.52% is expected in the next year compared to the current price of 21.1.